Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Design Therapeutics Inc shares valued at $2,953,792 were sold by William Arsani on Aug 13 ’25. At $5.25 per share, William Arsani sold 562,627 shares. The insider’s holdings dropped to 1,000,000 shares worth approximately $6.71 million following the completion of this transaction.
Also, Logos Opportunities Fund II LP purchased 217,627 shares, netting a total of over 1,083,783 in proceeds.
Before that, Logos Global Master Fund LP had added 345,000 shares to its account. In a trade valued at $1,718,100, the Director bought Design Therapeutics Inc shares for $4.98 each.
As published in a research note from Piper Sandler on May 07, 2024, Design Therapeutics Inc [DSGN] has been rated up from a Neutral to an Overweight and the price target has been revised to $12 from $6. Analysts at Piper Sandler downgraded the stock from ‘”an Overweight”‘ to ‘”a Neutral”‘ outlook in a report released in mid November. As of August 15, 2023, Wedbush has decreased its “an Outperform” rating to a “Neutral” for DSGN. Earlier on August 15, 2023, SVB Securities downgraded its rating. Their new recommendation was “a Market perform” for DSGN stock which previously was a “an Outperform”.
Analyzing DSGN Stock Performance
On last trading session, Design Therapeutics Inc [NASDAQ: DSGN] rose 1.36% to $6.71. The stock’s lowest price that day was $6.5593, but it reached a high of $7.085 in the same session. During the last five days, there has been a drop of approximately -3.31%. Over the course of the year, Design Therapeutics Inc shares have jumped approximately 34.20%.
Is Design Therapeutics Inc subject to short interest?
Stocks of Design Therapeutics Inc saw a sharp rise in short interest on 2025-09-30 jumping by 32936.0 shares to 3.55 million. Data from Yahoo Finance shows that the short interest on 2025-08-29 was 3.52 million shares. A jump of 0.93% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 18.76 of the overall float, the days-to-cover ratio (short ratio) jumped to 18.76.
Which companies own the most shares of Design Therapeutics Inc (DSGN)?
In terms of Design Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 10 in the next 12 months, up nearly 51.06% from the previous closing price of $6.62. Analysts anticipate Design Therapeutics Inc stock to reach 12 by 2025, with the lowest price target being 7. In spite of this, 2 analysts ranked Design Therapeutics Inc stock as Buy at the end of 2025. On August 15, 2023, RBC Capital Mkts assigned a price target of “a Sector perform” to the stock and downgraded coverage with a $7.
